Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Panetta

Vascular Surgery Great Neck, NY Medical Doctor

NPI 1184601072 CMS profile 7990

600 Northern Blvd, Suite 115, Great Neck, NY 11021

Open in the dashboard

General payments

$765

12 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Panetta of Great Neck, NY is reported in the CMS Open Payments database as having received $765 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 18th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115 4
2024 General $139 2
2023 General $142 1
2022 General $130 1
2020 General $11 1
2019 General $227 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Panetta
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas Panetta were reported at $115. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas Panetta Vascular Surgery median Middle half National median
2019 $227 $796 $226–$2,363 $163
2020 $11 $348 $118–$1,110 $114
2021 $0 $471 $158–$1,421 $132
2022 $130 $725 $222–$2,183 $149
2023 $142 $836 $257–$2,440 $160
2024 $139 $909 $252–$2,619 $164
2025 $115 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $275 4 payments
  2. NxStage Medical, Inc. $232 2 payments
  3. W. L. Gore & Associates, Inc. $105 1 payment
  4. Boston Scientific Corporation $88 3 payments
  5. Ethicon US, LLC $44 1 payment
  6. Merit Medical Systems Inc $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $765 12 payments
Products named General payments · program years 2019–2025
  1. NXSTAGE SYSTEM ONE $232 2 payments
  2. Venovo $142 1 payment
  3. NXSTAGE CARTRIDGE EXPRESS $130 1 payment
  4. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $105 1 payment
  5. VISTASEAL $44 1 payment
  6. PROLENE $44 1 payment
  7. ELUVIA $37 1 payment
  8. OptiCross 35 $37 1 payment
  9. Prelude Introducers $21 1 payment
  10. Merit MAK Kits $21 1 payment
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

65

Median for Vascular Surgery: 122

Drug cost

$1,051

Median for Vascular Surgery: $14,135

Branded share of claims

16.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 14 $449
Cilostazol Generic 20 $384
Ciprofloxacin Hcl Generic 20 $134
Clopidogrel Clopidogrel Bisulfate Brand 11 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$698,721

Of which drugs: $2,168

Medicare patients

285

Average age 72

Services billed

8,490

128 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 70%
Ischemic heart disease 59%
Heart failure 52%
Arthritis 45%
Atrial fibrillation 32%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 148 6,693 $688

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record